SUBSCRIBERS
Gilead Sciences' patent loss to Merck started with a broken friendship
Published Sun, Dec 18, 2016 · 09:50 PM
Washington
IF Gilead Sciences Inc has to pay Merck & Co US$2.54 billion in patent royalties, it may come down to the details of what happened between two scientists who once were close friends.
Merck claims its Idenix unit, which it bought in 2014 for about US$3.85 billion, developed a new class of compounds to treat the potentially deadly virus hepatitis C, which attacks the liver and afflicts as many as 150 million people globally.
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Consumer & Healthcare
‘Extreme’ climate blamed for world’s worst wine harvest in 62 years
Sheng Siong Q1 net profit up 9.3% on higher revenue
Nestle sales growth sputters on US slump, vitamin snags
Hermes Q1 sales jump 17% on strong China demand
Cordlife’s independent auditor to retire after issuing disclaimer of opinion on FY2023 financials
Cutting the cord?: Events leading up to Cordlife’s MOH suspension and arrests of its directors, ex-group CEO